Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Bone Marrow Transplant. 2022 May;57(5):781-789. doi: 10.1038/s41409-022-01621-w. Epub 2022 Mar 2.
Viral infection is one of the lethal adverse events after cord blood transplantation (CBT). Human leukocyte antigen (HLA) and killer immunoglobulin-like receptor (KIR) ligand divergences can increase the risk of viral infection due to conflicting interactions between virus-infected cells and immune cells. However, the relationship between these disparities and the frequency of viral infection after CBT remains to be evaluated. Herein, we have conducted a retrospective multicenter study to assess the effect of HLA and KIR ligand mismatches on viral infections after CBT. The study included 429 patients, among which 126 viral infections occurred before day 100. Viral infection was significantly associated with poorer overall survival (OS; hazard ratio [HR] 1.74, p < 0.01). Patients harboring ≥3 mismatches in the HLA allele and inhibitory KIR ligand mismatches (HLA & KIR mismatches) had a significantly greater prevalence of viral infection (HR 1.66, p = 0.04). Thus, patients with HLA & KIR mismatches had poorer outcomes in terms of non-relapse mortality (HR 1.61, p = 0.05). Our study demonstrates the unfavorable impacts of HLA & KIR mismatches on viral infections and non-relapse mortality after CBT. Evaluating the viral infection risk and performance of an appropriate and early intervention in high-risk patients and optimizing the graft selection algorithm could improve the outcome of CBTs.
病毒感染是脐带血移植(CBT)后致死的不良事件之一。人类白细胞抗原(HLA)和杀伤细胞免疫球蛋白样受体(KIR)配体的差异可能会由于受感染细胞与免疫细胞之间的冲突相互作用而增加病毒感染的风险。然而,这些差异与 CBT 后病毒感染的频率之间的关系仍有待评估。在此,我们进行了一项回顾性多中心研究,以评估 HLA 和 KIR 配体错配对 CBT 后病毒感染的影响。该研究纳入了 429 例患者,其中 126 例在第 100 天之前发生了病毒感染。病毒感染与总体生存(OS)显著相关(危险比[HR]1.74,p<0.01)。在 HLA 等位基因和抑制性 KIR 配体错配(HLA & KIR 错配)中存在≥3 个错配的患者中,病毒感染的发生率显著更高(HR 1.66,p=0.04)。因此,HLA & KIR 错配的患者在非复发死亡率方面的预后更差(HR 1.61,p=0.05)。我们的研究表明,HLA & KIR 错配对 CBT 后病毒感染和非复发死亡率有不利影响。评估高危患者的病毒感染风险并进行适当和早期干预,以及优化移植物选择算法,可能会改善 CBT 的结果。